Related Experiment Video

Updated: Aug 14, 2026

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
11:02

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response

Morimasa Wada1

  • 1Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka-shi, Fukuoka 812-8582, Japan. wada@biochem1.med.kyushu-u.ac.jp

Cancer Letters
|December 27, 2005
PubMed

Insights

ATP-binding cassette (ABC) transporters ABCB1 and ABCC2 play roles in drug resistance and protection from toxins. Genetic variations in these transporters may influence drug response and cancer risk.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Genetics

Background:

  • ATP-binding cassette (ABC) proteins, including ABCB1, ABCC1, ABCC2, and ABCG2, are implicated in multidrug resistance in cancer chemotherapy.
  • ABCB1 and ABCC2, with broad substrate specificity and apical localization in intestinal and liver cells, protect against xenobiotics.
  • Inter-individual differences in ABCB1 and ABCC2 activity and expression can impact drug response and sensitivity to toxic substances.

Purpose of the Study:

  • To review the physiological and toxicological significance of ABCB1 and ABCC2.
  • To examine the association between genetic variations in ABCB1 and ABCC2 genes and their biochemical function, expression levels, and tumor incidence.

Main Methods:

  • Literature review focusing on the roles of ABCB1 and ABCC2.
  • Analysis of studies investigating genetic variations in ABCB1 and ABCC2.
  • Synthesis of data on the impact of these variations on transporter function, expression, and disease association.

Main Results:

  • ABCB1 and ABCC2 are crucial in drug disposition and detoxification.
  • Genetic polymorphisms in ABCB1 and ABCC2 are linked to altered transporter activity and expression.
  • These genetic variations may influence individual susceptibility to drug toxicity and cancer development.

Conclusions:

  • ABCB1 and ABCC2 are key players in xenobiotic transport and drug response.
  • Understanding the genetic variations of ABCB1 and ABCC2 is vital for personalized medicine and risk assessment.
  • Further research into ABC transporter genetics can elucidate mechanisms of drug resistance and disease pathogenesis.

More Related Videos

ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography06:47

ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography

Published on: August 25, 2023

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...